ClinicalTrials.gg
CompletedNCT07539090Updated Oct 15, 2026

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

A Phase 1 interventional study of Vimseltinib and Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) in Healthy Participants, sponsored by Deciphera Pharmaceuticals, LLC. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Basic science

Updated Oct 15, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
  2. (BMI) from greater than or equal to (≥) 18.5 to less than or equal to ≤ 30 kilogram per square meter (kg/m\^2).
  3. Adequate organ function, blood and urine tests, as required by the protocol and as determined by Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
  2. Unwilling or unable to comply with the requirements of the protocol.
  3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Vimseltinib + Combined Oral Contraceptive (COC)

    Day 1 single dose of combined oral contraceptive (COC) (ethinyl estradiol \[EE\]/levonorgestrel \[LNG\]). Day 4 through 7, Day 11 and Day 14 single daily dose of Vimseltinib. Day 18 coadministration of COC (EE /LNG) with vimseltinib.

    Drug: Vimseltinib · Drug: Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

Interventions

  • Administered orally

  • DrugCombined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  2. PK: Area Under the Plasma Concentration-Time Curve from Time 0 up to Time t (AUC0-t), Where t is the Last Time Point at which the Concentration is Above the Lower Limit of Quantification, of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  3. PK: AUC from Time 0 to Infinity (AUC0-∞) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

Secondary outcomes

  1. PK: Apparent Systemic Clearance (CL/F) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  2. PK: Apparent Volume of Distribution Associated with the Terminal Phase (Vz/F) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  3. PK: Time to Maximum Observed Plasma Concentration (Tmax) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  4. PK: Terminal Elimination Phase Half-Life (t1/2) of EE and LNG

    Time frame: Predose up to 72 Hours Post Dose

  5. Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline through Day 35

  6. Safety: Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline through Day 21

  7. Safety: Number of Participants with Clinically Significant Change from Baseline in Vital Signs

    Time frame: Baseline through Day 21

07

Study locations

1 site
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Oct 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Jun 5, 2026
Primary completionActual
Oct 8, 2026
CompletionActual
Oct 8, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Enrollment
24 (estimated)→27 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    Enrollment 24 (estimated)→27 (actual)
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07539090
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Jun 5, 2026
Primary completion
Oct 8, 2026
Completion
Oct 8, 2026
Last update
Oct 15, 2026

Study contacts

Clinical Team
study director · Deciphera Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vimseltinib

Start the discussion